02157 LEPU BIO-B
- 3.190
- +0.140+4.59%
LEPU BIO-B News
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTACCEPTANCE OF THE NEW DRUG APPLICATION AND PRIORITYREVIEW GRANTED BY NMPA TOMRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
LEPU BIO-B: ARTICLES OF ASSOCIATION
LEPU BIO-B: AMENDMENTS TO THE ARTICLES OF ASSOCIATION
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTBREAKTHROUGH THERAPY DESIGNATION GRANTEDBY THE FDA TO MRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
LEPU BIO-B: Proxy Form for the Annual General Meeting to be held on June 19 2024
LEPU BIO-B: Next Day Disclosure Return
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTTHREE CLINICAL TRIAL RESULTSPRESENTED AT 2024 ASCO ANNUAL MEETING
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTUPDATE ON THE LICENSE AGREEMENT WITHASTRAZENECA FOR CMG901
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG004A FOR THE TREATMENT OF PANCREATIC CANCER
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
LEPU BIO-B: ARTICLES OF ASSOCIATION
Analysis
Price Target
No Data
No Data